APA (7th ed.) Citation

Marron, T., Segar, J., Berlin, J., Boccia, R., Spira, A., Powderly, J., . . . Misleh, J. (2024). 665P Safety, PK, immune activation, and clinical outcomes with RBS2418 treatment, an oral ENPP1 inhibitor, alone or in combination with pembrolizumab in advanced solid tumors. Annals of Oncology, 35, S523. https://doi.org/10.1016/j.annonc.2024.08.731

Chicago Style (17th ed.) Citation

Marron, T., et al. "665P Safety, PK, Immune Activation, and Clinical Outcomes with RBS2418 Treatment, an Oral ENPP1 Inhibitor, Alone or in Combination with Pembrolizumab in Advanced Solid Tumors." Annals of Oncology 35 (2024): S523. https://doi.org/10.1016/j.annonc.2024.08.731.

MLA (9th ed.) Citation

Marron, T., et al. "665P Safety, PK, Immune Activation, and Clinical Outcomes with RBS2418 Treatment, an Oral ENPP1 Inhibitor, Alone or in Combination with Pembrolizumab in Advanced Solid Tumors." Annals of Oncology, vol. 35, 2024, p. S523, https://doi.org/10.1016/j.annonc.2024.08.731.